Log in
OTCMKTS:CNBX

Cannabics Pharmaceuticals Stock Forecast, Price & News

$0.29
+0.02 (+7.41 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.27
Now: $0.29
$0.30
50-Day Range
$0.15
MA: $0.19
$0.30
52-Week Range
$0.07
Now: $0.29
$0.61
Volume87,460 shs
Average Volume310,887 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Current SymbolOTCMKTS:CNBX
CUSIPN/A
Phone+1-877-4242429
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.29
+0.02 (+7.41 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNBX News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cannabics Pharmaceuticals (OTCMKTS:CNBX) Frequently Asked Questions

How has Cannabics Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Cannabics Pharmaceuticals' stock was trading at $0.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CNBX shares have decreased by 3.3% and is now trading at $0.29.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Cannabics Pharmaceuticals?

Wall Street analysts have given Cannabics Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cannabics Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Cannabics Pharmaceuticals' key competitors?

What other stocks do shareholders of Cannabics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabics Pharmaceuticals investors own include Gran Tierra Energy (GTE), OrganiGram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).

Who are Cannabics Pharmaceuticals' key executives?

Cannabics Pharmaceuticals' management team includes the following people:
  • Mr. Eyal Barad, Co-Founder, CEO & Director (Age 55, Pay $257.72k)
  • Dr. Eyal Ballan Ph.D., Co-Founder & CTO (Age 44, Pay $257.83k)
  • Mr. Gabriel Yariv, Pres, COO & Director (Age 44)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 50)
  • Noam Permont, VP of PR & Investor Relations
  • Mr. David E. Price, Corp. Sec. & Corp. Counsel (Age 55)
  • Mr. Yasha Borstein, Chief Data Officer (Age 57)
  • Dr. Yaakov Waksman, Head of Cannabidiol Research (Age 68)
  • Dr. Gil Feiler, Head of Advisory Board & Bus. Devel. Advisor (Age 60)
  • Dr. Sigalit Ariely-Portnoy, Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board (Age 56)

What is Cannabics Pharmaceuticals' stock symbol?

Cannabics Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX."

How do I buy shares of Cannabics Pharmaceuticals?

Shares of CNBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cannabics Pharmaceuticals' stock price today?

One share of CNBX stock can currently be purchased for approximately $0.29.

What is Cannabics Pharmaceuticals' official website?

The official website for Cannabics Pharmaceuticals is www.cannabics.com.

How can I contact Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The company can be reached via phone at +1-877-4242429.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.